Celldex Therapeutics, Inc (CLDX) Stock Price

CLDXStock

$27.53+3.69%52W

Market Cap$2.16B

P/E—

PEG Ratio—

Div yield—

Beta1.01

CLDX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-27.31%

Price vs S&P 500 (4W)-26.02%

VGM Score24.49

Book Value / Share (Quarterly)$9.10

P/TBV (Annual)3.61x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-13.17%

Cash Flow / Share (Quarterly)$-3.08

Price vs S&P 500 (YTD)-10.56%

Gross Margin (TTM)17.65%

Net Profit Margin (TTM)-147787.97%

EPS (TTM)$-4.36

10-Day Avg Trading Volume1.54M

EPS Excl Extra (TTM)$-4.36

Revenue Growth (5Y)-26.94%

EPS (Annual)$-3.90

ROI (Annual)-49.08%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-5465.53%

Cash / Share (Quarterly)$9.14

Revenue Growth QoQ (YoY)-96.99%

ROA (Last FY)-44.38%

Revenue Growth TTM (YoY)-97.27%

EBITD / Share (TTM)$-4.65

ROE (5Y Avg)-30.88%

Operating Margin (TTM)-159627.22%

Cash Flow / Share (Annual)$-3.21

P/B Ratio3.03x

P/B Ratio (Quarterly)4.09x

Net Income / Employee (Annual)$-1,306,900

EV / Revenue (TTM)13382.68x

Net Interest Coverage (TTM)-740.36x

ROA (TTM)-47.61%

EPS Incl Extra (Annual)$-3.90

Current Ratio (Annual)10.49x

Quick Ratio (Quarterly)11.71x

3-Month Avg Trading Volume1.32M

52-Week Price Return3.69%

Revenue / Employee (TTM)$800

Tangible BV / Share (Quarterly)$8.76

P/S Ratio (Annual)1399.30x

Asset Turnover (Annual)0.00x

52-Week High$45.14

Operating Margin (5Y Avg)-6007.73%

EPS Excl Extra (Annual)$-3.90

CapEx CAGR (5Y)11.86%

Tangible BV CAGR (5Y)22.86%

26-Week Price Return-17.40%

Quick Ratio (Annual)10.21x

13-Week Price Return-22.12%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.82x

Enterprise Value$2.11B

Revenue / Share Growth (5Y)-37.80%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)8.43%

Revenue / Employee (Annual)$7,800

Inventory Turnover (Annual)0.80x

Pretax Margin (Annual)-16748.03%

Cash / Share (Annual)$7.79

3-Month Return Std Dev46.30%

Gross Margin (5Y Avg)44.59%

Net Income / Employee (TTM)$-1,517,900

ROE (Last FY)-49.08%

Net Interest Coverage (Annual)-55.51x

EPS Basic Excl Extra (Annual)$-3.90

P/FCF (TTM)69.43x

Receivables Turnover (TTM)0.99x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.36

Receivables Turnover (Annual)1.14x

ROI (TTM)-52.35%

P/S Ratio (TTM)13683.03x

Pretax Margin (5Y Avg)-5466.52%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$7.51

Price vs S&P 500 (52W)-11.84%

Year-to-Date Return1.36%

5-Day Price Return-6.46%

EPS Normalized (Annual)$-3.90

ROA (5Y Avg)-28.48%

Net Profit Margin (Annual)-16748.03%

Month-to-Date Return-15.06%

Cash Flow / Share (TTM)$-2.58

EBITD / Share (Annual)$-4.28

Operating Margin (Annual)-18599.81%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-30.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.36

P/TBV (Quarterly)4.25x

P/B Ratio (Annual)3.42x

Inventory Turnover (TTM)0.80x

Pretax Margin (TTM)-147787.97%

Book Value / Share (Annual)$7.92

Price vs S&P 500 (13W)-24.81%

Beta1.01x

P/FCF (Annual)127.32x

Revenue / Share (TTM)$0.00

ROE (TTM)-52.35%

52-Week Low$22.10

vGradeF

gGradeF

mGradeC

vgmGradeD

CLDX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.06	-$0.94	+11.41%(+$0.12)
Q1 2026	May 7, 2026	-$1.13	-$1.18	-4.22%(-$0.05)
Q4 2025	Feb 25, 2026	-$1.00	-$1.22	-22.50%(-$0.22)
Q3 2025	Nov 10, 2025	-$0.89	-$1.01	-13.16%(-$0.12)
Q2 2025	Aug 7, 2025	-$0.84	-$0.85	-0.96%(-$0.01)

CLDX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.23

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About Celldex Therapeutics, Inc

Celldex Therapeutics develops monoclonal and bispecific antibodies to treat mast cell-mediated inflammatory, allergic, and autoimmune diseases. The company combines research in mast cell biology with manufacturing and commercialization capabilities to advance its therapeutic pipeline.